DUBLIN--(BUSINESS WIRE)--The "Digital Dose Inhalers Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The digital dose inhalers market analysis considers sales from both metered-dose and soft mist inhalers and dry powder inhalers. The analysis also considers the sales of digital dose inhalers in Asia, Europe, North America, and RoW.
In 2018, the metered dose and soft mist inhalers segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as delivery of accurate dose during inhalation, cost-effectiveness will play a significant role in the metered-dose and soft mist inhalers segment to maintain its market position.
Also, our global digital dose inhalers market report looks at factors such as increasing prevalence of chronic respiratory diseases, increasing product launches by prominent players, and technological advances. However, high costs associated with digital dose inhalers, lack of awareness and interoperability, and limited availability of digital dose inhalers and digital security issues may hamper the growth of the digital dose inhalers industry over the forecast period.
Technological advancements
Digital dose inhalers or smart inhalers are an advanced type of inhalers, which help to achieve an effective outcome for COPD and asthma. Pharmaceutical companies are developing smart mist inhalers that optimize and improve drug delivery in patients with COPD.
Market vendors are increasingly integrating Bluetooth technology and digitalizing inhaler devices to minimize common errors by measuring patient inhalation, increase the drug delivery efficacy, reduce health care costs, improve medication adherence, and enhance patient outcome. Such benefits of technological advancements will lead to the expansion of the global digital dose inhalers market at a CAGR of almost 13% during the forecast period.
Rising integration of AI and the adoption of IoT
Digitalization has opened the doors for healthcare professionals to improve the treatment of asthma and COPD. AI technology uses algorithms and software to analyze complex medical data and minimizes the need for direct human input. Moreover, IoT based digital inhalers help customers to monitor their condition, understand the measurement of dosage, and prevent subsequent respiratory attacks.
The sensors integrated digital dose inhaler systems help in minimizing emergency visits reducing risks and enhances patient outcome. This rise in the integration of AI and IoT is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global digital dose inhalers market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading digital dose inhalers manufacturers, that include:
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis AG
- OPKO Health Inc.
- Teva Pharmaceutical Industries Ltd.
Also, the digital dose inhalers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Metered dose and soft mist inhalers - Market size and forecast 2018-2023
- Dry powder inhalers - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- RoW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
- Rising integration of AI and adoption of IoT
- Business strategies
- Growing internet connectivity and use of smartphone devices
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis AG
- OPKO Health Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/x921w1
